We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

117 hedge funds and large institutions have $785M invested in Acceleron Pharma in 2015 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 57 increasing their positions, 24 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 24

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

2% more funds holding

Funds holding: 115 → 117 (+2)

18% less capital invested

Capital invested by funds: $956M → $785M (-$171M)

36% less call options, than puts

Call options by funds: $3.25M | Put options by funds: $5.1M

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
117
Holders Change
+2
Holders Change %
+1.74%
% of All Funds
3.15%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.08%
New
19
Increased
57
Reduced
24
Closed
17
Calls
$3.25M
Puts
$5.1M
Net Calls
-$1.85M
Net Calls Change
-$847K

Top Buyers

Rank Fund Capital Flow
1
ORI
Oak Ridge Investments
Illinois
+$7.84M
2
PCM
Pentwater Capital Management
Florida
+$4.2M
3
PI
Putnam Investments
Massachusetts
+$4.05M
4
BFA
BlackRock Fund Advisors
California
+$3.75M
5
SFM
Sphera Funds Management
Israel
+$3.23M

Top Sellers

Rank Fund Capital Flow
1
PC
PointState Capital
New York
-$18.1M
2
PVMCI
Polaris Venture Management Co IV
Massachusetts
-$16.4M
3
ICAP
Independence Capital Asset Partners
Colorado
-$13.8M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$13.6M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$7M
Name Holding Trade Value Shares
Change 		Change in
Stake
IHM
26
Iguana Healthcare Management
New York
$4.75M -$807K -25,000 -14%
PI
27
Putnam Investments
Massachusetts
$3.97M +$4.05M +125,472 New
TC
28
TFS Capital
Pennsylvania
$3.76M +$3.11M +96,388 +431%
CS
29
Credit Suisse
Switzerland
$3.73M +$299K +9,271 +9%
UBS AM
30
UBS AM
Illinois
$3.66M +$164K +5,092 +5%
Deutsche Bank
31
Deutsche Bank
Germany
$3.64M +$569K +17,631 +18%
BG
32
BlackRock Group
United Kingdom
$3.49M +$332K +10,275 +10%
AllianceBernstein
33
AllianceBernstein
Tennessee
$3.36M +$1.46M +45,350 +74%
BIM
34
BlackRock Investment Management
Delaware
$3.3M +$987K +30,577 +42%
CS
35
Candriam SCA
Luxembourg
$3.16M +$1.03M +32,000 +47%
SFM
36
Sphera Funds Management
Israel
$3.16M +$3.23M +100,000 New
Principal Financial Group
37
Principal Financial Group
Iowa
$2.99M +$1.01M +31,400 +50%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$2.95M +$688K +21,327 +30%
NLVP
39
New Leaf Venture Partners
New York
$2.84M +$2.9M +89,738 New
EAM
40
Eventide Asset Management
Massachusetts
$2.76M – – –
TA
41
Teachers Advisors
New York
$2.47M +$272K +8,443 +12%
Geode Capital Management
42
Geode Capital Management
Massachusetts
$2.46M +$270K +8,358 +12%
WSA
43
Wall Street Associates
California
$2.4M -$96.8K -3,000 -4%
TCIM
44
TIAA CREF Investment Management
New York
$2.31M +$505K +15,653 +27%
Millennium Management
45
Millennium Management
New York
$2.27M +$2.32M +71,865 New
Renaissance Technologies
46
Renaissance Technologies
New York
$2.03M +$2.08M +64,300 New
TD Asset Management
47
TD Asset Management
Ontario, Canada
$1.96M -$48.4K -1,500 -2%
TI
48
Turner Investments
Pennsylvania
$1.83M +$1.86M +57,740 New
TI
49
Telemetry Investments
New York
$1.71M +$1.11M +34,500 +177%
HCMT
50
Highland Capital Management (Texas)
Texas
$1.69M -$210K -6,500 -11%
1
2
3 4 5

XLRN Hedge Fund Activity: Q2 2015 in Review

117 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2015, worth a combined $785M — down 18% from $956M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new XLRN positions and 17 closed out — a net gain of 2 holders — while 57 added to existing stakes and 24 trimmed.

The largest buyer was Oak Ridge Investments, adding an estimated $7.84M. The largest seller was PointState Capital, exiting entirely with an estimated $18.1M sold.

  • 117 institutional investors held Acceleron Pharma (XLRN) as of Q2 2015, up from 115 in Q1 2015.
  • Funds reported $785M of Acceleron Pharma stock for Q2 2015, down 18% quarter-over-quarter.
  • 19 funds opened new Acceleron Pharma positions in Q2 2015 and 17 closed out, a net change of +2 holders.
  • The largest Acceleron Pharma buyer in Q2 2015 was Oak Ridge Investments, an estimated $7.84M added.
  • The largest Acceleron Pharma seller in Q2 2015 was PointState Capital, an estimated $18.1M sold.

Based on aggregated 13F filings for Q2 2015.